JPH08510748A - リポソームが誘発する生理的副作用の低減 - Google Patents
リポソームが誘発する生理的副作用の低減Info
- Publication number
- JPH08510748A JPH08510748A JP7500895A JP50089595A JPH08510748A JP H08510748 A JPH08510748 A JP H08510748A JP 7500895 A JP7500895 A JP 7500895A JP 50089595 A JP50089595 A JP 50089595A JP H08510748 A JPH08510748 A JP H08510748A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- liposome
- liposomes
- agent
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.生理活性剤と、表面改質剤とアンカーとを含む表面剤で改質された分子及び 脂質を有する脂質二分子膜とを含むリポソームの生理的副作用低減有効量をリポ ソームが誘発する生理的副作用を低減するための医薬組成物の製造のための使用 。 2.リポソームが、200nmから5000nmまでの直径を有している請求の 範囲1の使用。 3.リポソームが、400nmから5000nmまでの直径を有している請求の 範囲2の使用。 4.リポソームが、400nmから1000nmまでの直径を有している請求の 範囲3の使用。 5.ユニラメラリポソームが、ラージユニラメラリポソームである請求の範囲1 の使用。 6.リポソームが、嵌合−融合リポソームである請求の範囲1の使用。 7.リポソームが、マルチラメラリポソームである請求の範囲1の方法。 8.マルチラメラリポソームが、その水性区画に取り込まれた溶質を含み、各水 性区画内の溶質の濃度が実質的に等しい請求の範囲7のリポソーム。 9.二分子膜内の表面剤改質分子の濃度が、2モル%以上である請求の範囲1の 使用。 10.表面剤改質分子の濃度が、5モル%以上である請求の範囲9の使用。 11.表面剤改質分子の濃度が、10モル%以上である請求の範囲1 0の使用。 12.表面改質剤が、ジカルボン酸である請求の範囲1の使用。 13.ジカルボン酸が、コハク酸、グルタル酸、アジピン酸、ビメリン酸、スベ リン酸、酒石酸、粘液酸、テトラフルオロコハク酸又はヘキサフルオログルタル 酸である請求の範囲12の使用。 14.表面改質剤が、モノカルボン酸である請求の範囲1の使用。 15.モノカルボン酸が、酢酸、プロピオン酸、酪酸、吉草酸、グリコール酸、 乳酸、トリフルオロ酢酸、ペンタフルオロプロピオン酸又はヘプタフルオロ酪酸 である請求の範囲14の使用。 16.表面改質剤が、スルホ脂質である請求の範囲1の使用。 17.スルホ脂質が、ビス(スクシンイミドオキシカルボニルオキシ)エチルス ルホン、N−スクシンイミジル−S−アセチルチオアセテート又は2−イミノチ オラン(トラウト試薬)である請求の範囲16の使用。 18.表面改質剤が、グルタル酸である請求の範囲1の使用。 19.アンカーが、リン脂質である請求の範囲1の使用。 20.リン脂質が、飽和アシル鎖を有している請求の範囲19の使用。 21.飽和アシル鎖が、パルミテート鎖である請求の範囲20の使用。 22.リン脂質が、ジパルミトイルホスファチジルエタノールアミン(DPPE )である請求の範囲19の使用。 23.アンカーが、両親媒性蛋白質である請求の範囲1の使用。 24.表面剤改質分子が、リン脂質アンカーとスペーサー基を含み、そのスペー サー基が、リン脂質アンカーのグリセロール骨格及びリン脂質アンカーのホスフ ェート基に結合することができる一つ又はそれ以上の有機官能基を含む請求の範 囲1の使用。 25.官能基が、水酸基、チオール基、エポキシド基又はアミン基である請求の 範囲24の使用。 26.スペーサー基が、エチレングリコール又はポリエチレングリコールである 請求の範囲24の使用。 27.生理活性剤が、造影剤、抗菌剤、抗ウイルス剤、抗真菌剤、駆虫剤、殺腫 瘍剤、代謝拮抗薬、炭水化物、ポリペプチド、ペプチド、蛋白質、トキシン、酵 素、ホルモン、神経伝達物質、糖蛋白、リポ蛋白、免疫グロブリン、免疫調節剤 、血管拡張剤、染料、放射線標識剤、放射線不透性化合物、蛍光化合物、レセプ ター結合分子、抗炎症剤、散瞳化合物、局所麻酔剤、麻酔剤、ビタミン、核酸、 ポリヌクレオチド、ヌクレオシド、ヌクレオチド、MRI、放射線又は水溶性ヨ ウ素標識造影剤、それらの混合物及び薬理学的に許容され得る塩、又はそれらの 混合物である請求の範囲1の使用。 28.水溶性ヨウ素標識造影剤が、イオヘキソール、イオパミドール、イオキソ グレート、イオトロラン、イオバーソル、イオタラメート、ヨージミド、ヨージ パミド、イオプロミド、メトリザミド、イオペントール、ヨージキサノール、デ ィアトリゾエート、イオトロクス酸、それらの混合物及び薬理学的に許容され得 る塩からなる群から選ばれる請求の範囲27の使用。 29.水溶性ヨウ素標識造影剤が、イオトロランである請求の範囲28の使用。 30.リポソームの生理的副作用低減有効量が、動物の体重1kg当たりリポソ ーム50mgである請求の範囲1の使用。 31.抗炎症剤に関連したリポソーム誘発生理的副作用を低減するための医薬組 成物を製造するために、生理活性剤としての抗炎症剤と脂 質及び表面剤改質分子を有する脂質二分子膜とを含むリポソームを生理的副作用 低減有効量の使用において、該抗炎症剤がリポソーム中にカプセル化されていな いもの。 32.抗炎症剤が、ステロイドである請求の範囲31の使用。 33.抗炎症剤が、非ステロイド系抗炎症剤である請求の範囲31の使用。 34.非ステロイド系抗炎症剤が、インドメタシンである請求の範囲33の使用 。 35.生理活性剤と、脂質及び表面剤改質分子を有する脂質二分子膜とを含むリ ポソームの生理的副作用低減有効量を含有する、リボソーム誘発生理的副作用を 低減するのに適応した組成のリポソーム組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6592893A | 1993-05-21 | 1993-05-21 | |
US08/065,928 | 1993-05-21 | ||
US20765194A | 1994-03-07 | 1994-03-07 | |
US08/207,651 | 1994-03-07 | ||
PCT/US1994/005824 WO1994027580A1 (en) | 1993-05-21 | 1994-05-20 | Reduction of liposome-induced adverse physiological reactions |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08510748A true JPH08510748A (ja) | 1996-11-12 |
Family
ID=26746185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7500895A Withdrawn JPH08510748A (ja) | 1993-05-21 | 1994-05-20 | リポソームが誘発する生理的副作用の低減 |
Country Status (15)
Country | Link |
---|---|
US (2) | US5614214A (ja) |
EP (2) | EP1118326A3 (ja) |
JP (1) | JPH08510748A (ja) |
KR (1) | KR960702297A (ja) |
AT (1) | ATE210966T1 (ja) |
AU (1) | AU680513B2 (ja) |
CA (1) | CA2160118A1 (ja) |
DE (2) | DE69429511T2 (ja) |
DK (1) | DK0699068T3 (ja) |
ES (2) | ES2165875T3 (ja) |
GR (1) | GR20010300075T1 (ja) |
NO (1) | NO954691L (ja) |
NZ (1) | NZ267310A (ja) |
PT (1) | PT699068E (ja) |
WO (1) | WO1994027580A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995012386A1 (en) * | 1993-11-04 | 1995-05-11 | Schering Aktiengesellschaft | Charged liposome preparation |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
DE69519802T2 (de) * | 1994-10-14 | 2001-04-19 | Liposome Co Inc | Etherlipid-liposomen und deren therapeutische verwendung |
US6673364B1 (en) | 1995-06-07 | 2004-01-06 | The University Of British Columbia | Liposome having an exchangeable component |
US5942246A (en) * | 1996-02-16 | 1999-08-24 | The Liposome Company, Inc. | Etherlipid containing multiple lipid liposomes |
US6667053B1 (en) | 1996-02-16 | 2003-12-23 | Elan Pharmaceuticals, Inc. | D and L etherlipid stereoisomers and liposomes |
USRE39042E1 (en) * | 1996-02-16 | 2006-03-28 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
US6007839A (en) * | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
US5965159A (en) * | 1996-02-16 | 1999-10-12 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US6734171B1 (en) | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
EP0976394A1 (en) * | 1998-07-30 | 2000-02-02 | Biosearch Italia S.p.A. | New injectable formulations |
US6593308B2 (en) * | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
WO2002080883A2 (en) * | 2001-03-27 | 2002-10-17 | Phares Pharmaceutical Research N.V. | Method and composition for solubilising a biologically active compound with low water solubility |
AU2002311616B2 (en) * | 2001-06-25 | 2007-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method for preparation of vesicles loaded with biological material and different uses thereof |
US20030180348A1 (en) * | 2002-03-22 | 2003-09-25 | Levinson R. Saul | Transcellular drug delivery system |
US6811777B2 (en) | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
US7462703B2 (en) * | 2003-01-31 | 2008-12-09 | Max-Delbruck-Centrum Fur Molekulare Medizin | Agent for gene transfer |
CN1319520C (zh) * | 2005-02-03 | 2007-06-06 | 上海交通大学 | 核苷膦酸类化合物的脂质体和脂质复合物制剂 |
WO2008063808A2 (en) * | 2006-10-24 | 2008-05-29 | Northwestern University | Encapsulated peptide amphiphile nanostructures |
WO2010042658A1 (en) | 2008-10-07 | 2010-04-15 | Bioparadox, Llc | Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities |
EP2486923B1 (en) * | 2011-02-11 | 2015-09-09 | Dr. Felix Jäger und Dr. Stefan Drinkuth Laborgemeinschaft OHG | Histone deacetylase (HDAC) inhibiting compounds and method of making same |
US20140356893A1 (en) | 2013-06-04 | 2014-12-04 | Allan Mishra | Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation |
US20210154307A1 (en) * | 2019-11-07 | 2021-05-27 | Northeastern University | Cationic nanostructures for intra-cartilage delivery of therapeutics and contrast agents |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3577446A (en) * | 1968-09-09 | 1971-05-04 | American Home Prod | Phosphatidylalkanolamine derivatives |
US3993754A (en) * | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
US4086257A (en) * | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
CH624011A5 (ja) * | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
CH621479A5 (ja) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4522803A (en) * | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US5030453A (en) * | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4588578A (en) * | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
EP0153955A1 (en) * | 1983-09-06 | 1985-09-11 | Health Research, Inc. | Liposome delivery method for decreasing the toxicity of an antitumor drug |
US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
CA1264668C (en) * | 1984-06-20 | 1990-01-23 | EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES | |
US5008050A (en) * | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
CA1270198C (en) * | 1984-08-08 | 1990-06-12 | Marcel B Bally | ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES |
US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
JPS6188887A (ja) * | 1984-10-08 | 1986-05-07 | Meito Sangyo Kk | 酵素法1−o−アルキル−2−アシルグリセロリン脂質誘導体の製法 |
US4975282A (en) * | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
EP0231261B1 (en) * | 1985-07-05 | 1994-04-06 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
PH26160A (en) * | 1985-08-19 | 1992-03-18 | Univ Texas | Pharmaceutical compositions consisting of acylated phospholipids |
US5041278A (en) * | 1985-10-15 | 1991-08-20 | The Liposome Company, Inc. | Alpha tocopherol-based vesicles |
US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
NZ223660A (en) * | 1987-03-05 | 1990-11-27 | Liposome Co Inc | Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity |
CH672733A5 (ja) * | 1987-05-22 | 1989-12-29 | Bracco Ind Chimica Spa | |
US5080833A (en) * | 1987-09-21 | 1992-01-14 | Kabushiki Kaisha Toshiba | Immobilization of bioactive substance on lipid composition containing modified lipid compound |
JPH04505616A (ja) * | 1989-05-15 | 1992-10-01 | ザ リポソーム カンパニー,インコーポレイテッド | プロトン勾配によるリポソームへの薬剤の蓄積 |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE69108254T2 (de) * | 1990-10-09 | 1995-10-19 | Vestar Inc | Vesikel aus phospholipidderivaten mit einem succinimidylsubstituenten. |
US5313804A (en) * | 1993-04-23 | 1994-05-24 | Maritime Geothermal Ltd. | Direct expansion geothermal heat pump |
-
1994
- 1994-05-20 KR KR1019950705072A patent/KR960702297A/ko not_active Application Discontinuation
- 1994-05-20 AU AU69568/94A patent/AU680513B2/en not_active Ceased
- 1994-05-20 DE DE69429511T patent/DE69429511T2/de not_active Expired - Fee Related
- 1994-05-20 DK DK94918106T patent/DK0699068T3/da active
- 1994-05-20 CA CA002160118A patent/CA2160118A1/en not_active Abandoned
- 1994-05-20 EP EP01100692A patent/EP1118326A3/en not_active Withdrawn
- 1994-05-20 DE DE1118326T patent/DE1118326T1/de active Pending
- 1994-05-20 ES ES94918106T patent/ES2165875T3/es not_active Expired - Lifetime
- 1994-05-20 WO PCT/US1994/005824 patent/WO1994027580A1/en active IP Right Grant
- 1994-05-20 EP EP94918106A patent/EP0699068B1/en not_active Expired - Lifetime
- 1994-05-20 ES ES01100692T patent/ES2193005T1/es active Pending
- 1994-05-20 AT AT94918106T patent/ATE210966T1/de not_active IP Right Cessation
- 1994-05-20 NZ NZ267310A patent/NZ267310A/en unknown
- 1994-05-20 US US08/247,053 patent/US5614214A/en not_active Expired - Lifetime
- 1994-05-20 PT PT94918106T patent/PT699068E/pt unknown
- 1994-05-20 JP JP7500895A patent/JPH08510748A/ja not_active Withdrawn
-
1995
- 1995-05-04 US US08/433,665 patent/US5662930A/en not_active Expired - Lifetime
- 1995-11-20 NO NO954691A patent/NO954691L/no not_active Application Discontinuation
-
2001
- 2001-12-31 GR GR20010300075T patent/GR20010300075T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69429511T2 (de) | 2002-05-16 |
EP1118326A2 (en) | 2001-07-25 |
NO954691D0 (no) | 1995-11-20 |
ES2165875T3 (es) | 2002-04-01 |
ATE210966T1 (de) | 2002-01-15 |
AU680513B2 (en) | 1997-07-31 |
CA2160118A1 (en) | 1994-12-08 |
DE69429511D1 (de) | 2002-01-31 |
DK0699068T3 (da) | 2002-03-11 |
WO1994027580A1 (en) | 1994-12-08 |
GR20010300075T1 (en) | 2001-12-31 |
PT699068E (pt) | 2002-06-28 |
KR960702297A (ko) | 1996-04-27 |
EP1118326A3 (en) | 2002-07-31 |
US5662930A (en) | 1997-09-02 |
ES2193005T1 (es) | 2003-11-01 |
NO954691L (no) | 1995-11-20 |
US5614214A (en) | 1997-03-25 |
NZ267310A (en) | 1996-09-25 |
EP0699068A1 (en) | 1996-03-06 |
DE1118326T1 (de) | 2002-04-18 |
EP0699068B1 (en) | 2001-12-19 |
AU6956894A (en) | 1994-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08510748A (ja) | リポソームが誘発する生理的副作用の低減 | |
AU654120B2 (en) | Solid tumor treatment method and composition | |
JP5117648B2 (ja) | カチオン性peg脂質および使用方法。 | |
EP0243446B1 (en) | Alpha tocopherol-based vesicles | |
EP1272225B1 (en) | Lipid-based systems for targeting diagnostic agents | |
US5043165A (en) | Novel liposome composition for sustained release of steroidal drugs | |
JP2706642B2 (ja) | ステロールリポソームの調製方法 | |
US6514523B1 (en) | Carrier particles for drug delivery and process for preparation | |
US4310505A (en) | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances | |
JPH10507172A (ja) | リポソーム剤 | |
US20030113369A1 (en) | Liposomes with enhanced circulation time and method of treatment | |
WO2005021012A1 (ja) | ゲムシタビン封入薬剤担体 | |
JP2634047B2 (ja) | アルファトコフェロールをベースとした小胞体 | |
JP2568034B2 (ja) | 生物学的活性物質を含有するステロイドリポソーム含有生体内投与剤 | |
Parr | Circulation lifetimes and tumor accumulation of liposomal drug delivery systems | |
JP2706649B2 (ja) | ステロールベシクル中への化合物の捕捉方法 | |
Scherphof et al. | In Vivo Uptake and Processing of Liposomes by Parenchymal and Non-Parenchymal Liver Cells; Application to Immunotherapeutic Treatment of Hepatic Metastases | |
JPH0832623B2 (ja) | ステロイドリポソ−ム | |
VV | STUDIES OF FACTORS INFLUENCING DRUG EFFLUX RATES FROM LLLaLGGL GLL GGG LL GGGGGGGG GG GGGGaGGG LLLL GGGGGS Ву |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040727 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040716 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041012 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041122 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20050314 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050524 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070724 Year of fee payment: 9 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080724 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |